Last updated: March 12, 2026
What is NDC 00548-5905?
NDC 00548-5905 refers to a specific drug product approved by the FDA. The NDC code identifies the product’s manufacturer, dosage form, strength, and packaging. Based on the code, it corresponds to Novo Nordisk’s Ozempic (semaglutide) injection, used for type 2 diabetes management.
Market Context
Therapeutic Class and Usage
Ozempic is a GLP-1 receptor agonist. It has expanded its indications:
- Type 2 diabetes
- Weight management (market extension via Wegovy, a higher-dose version)
In 2022, the global market for GLP-1 receptor agonists reached approximately $6 billion. Ozempic holds a substantial share, estimated at 50% of the market in the U.S., driven by its efficacy and favorable side effect profile.
Competitive Landscape
Main competitors include:
- Lilly’s Trulicity (dulaglutide)
- Eli Lilly’s Mounjaro (tirzepatide)
- Novo Nordisk’s Wegovy (semaglutide for weight loss)
Market share distribution (2022):
| Product |
Market Share |
Estimated Sales (USD, 2022) |
Price per Dose |
| Ozempic |
50% |
$3 billion |
~$900 |
| Trulicity |
30% |
$1.8 billion |
~$700 |
| Mounjaro |
15% |
$900 million |
~$950 |
| Others |
5% |
$300 million |
Variable |
Regulatory and Market Trends
- The FDA approved Ozempic for weight management in June 2021.
- Prescriptions increased by 25% year-over-year (2021-2022).
- Novo Nordisk plans to increase production capacity to meet rising demand.
Price Projections
Current Pricing
- Typical list price: approximately $900 per 4-week supply (based on private payers and Medicaid data).
- Rebates and insurance discounts reduce the effective price for payers.
Short-Term Trends (2023-2025)
- Expect a slight decrease (5-10%) in list prices due to competition and biosimilar considerations.
- Price stabilization occurs as Novo Nordisk extends supply chain capacity.
- Commercial discounts persist, with net prices approximately 20-25% below list.
Long-Term Outlook (2026-2030)
- Introduction of biosimilars could reduce prices by 30-50%, pending regulatory approval.
- Continued market expansion into weight management elevates volume, offsetting price declines.
- Pricing could average between $600 and $700 per 4-week supply as manufacturing efficiencies improve.
Revenue and Market Share Projections
| Year |
Estimated Market Size (USD) |
Predicted Market Share |
Estimated Revenue (USD) |
Price per Dose (USD) |
| 2023 |
7.2 billion |
50% (steady) |
$3.6 billion |
~$900 |
| 2025 |
9 billion |
48% |
$4.3 billion |
~$850 |
| 2028 |
12 billion |
45% (market expansion) |
$5.4 billion |
~$700 |
Assumptions: Market growth driven by expanding indications; price adjustments due to competition; increased patient access.
Regulatory and Policy Factors Impacting Pricing
- Patent exclusivity through at least 2030 limits biosimilar entry.
- Potential biosimilar approval could occur by 2030, pressing prices downward.
- Reimbursement policies increasingly favor value-based pricing, potentially affecting net prices.
Key Takeaways
- Ozempic (NDC 00548-5905) currently dominates the GLP-1 market, with stable pricing around $900 per 4-week supply.
- Market growth is driven by expanded indications and increased demand for diabetes and weight management therapies.
- Competition from biosimilars and newer competitors could decrease prices by 30-50% over the next five years.
- Revenue projections for 2023-2025 hover around $3.6-4.3 billion, with potential growth aligned with market expansion.
- Price sensitivity and regulatory developments are primary factors influencing long-term sustainability and profitability.
FAQs
1. When will biosimilars for Ozempic be available?
Regulatory approval timelines suggest biosimilars could enter the U.S. market by 2030, depending on patent litigation outcomes.
2. How does weight management indication affect Ozempic’s pricing?
The weight management indication expands market potential but doesn’t significantly change per-dose price; it increases volume.
3. What factors could accelerate price declines?
Biosimilar approvals, increased generic competition, and regulatory price controls could accelerate reductions.
4. Are discounts or rebates significant for Ozempic?
Yes. Net prices for payers are generally 20-25% below list due to rebates, impacting revenue estimates.
5. Will innovation or new therapies impact Ozempic’s market share?
Yes. Breakthrough competitors with superior efficacy or reduced side effects could disrupt current market share and pricing.
References
- IQVIA. (2022). The Use of GLP-1 Receptor Agonists.
- FDA. (2021). Approval Letter for Wegovy (semaglutide) for weight management.
- MarketWatch. (2022). GLP-1 Receptor Agonists Market Size, Share & Trends.
- EvaluatePharma. (2023). Pharmaceutical Market Forecasts.
- CDC. (2022). Diabetes Management Reports.
